| Date | Title | Description |
| 29.01.2026 | uMotif Posts Strong Growth, Earns Market Accolades for eCOA Platform, Demonstrates Continued Clinical Trial Industry Leadership in 2025 | Everest Group gives uMotif highest possible technology rating in eCOA market assessment; Chief Scientific Officer Florence Mowlem PhD leads C-Path publication of industry-wide Event-Driven eDiary best practices in Nature Digital Medicine; f... |
| 15.12.2025 | uMotif Chief Scientific Officer Leads Publication of Fundamental Work Detailing Industry-Wide Recommendations for Adopting Event-Driven eDiaries in Clinical Trials | On behalf of the Critical Path Institute (C-Path) Florence Mowlem PhD, led this much-needed project, providing 10 best practices for EDeD design and implementation to support clinical trial data capture, along with co-authors from Top 10 ph... |
| 03.11.2025 | uMotif Harnesses AI to Deliver Faster, Higher-Quality Clinical Trials with MotifAI Assistant | AI-driven, multi-phase automation initiative across uMotif's product portfolio helps uMotif study teams enhance accuracy, accelerate timelines, and improve data quality for sponsors and CRO partners
BOSTON and LONDON, Nov. 3, 2025 /PRNewswi... |
| 16.09.2025 | uMotif to Showcase Modern eConsent and eCOA Platform to Support the Pivotal Patient-Site Relationship in Clinical Trials at Fall 2025 Life Sciences Conferences | uMotif provides a modern, all-in-one eConsent/eCOA platform for clinical trials and real-world studies
CEO Steve Rosenberg, Chief Patient Officer Bruce Hellman, Chief Scientific Officer Florence Mowlem PhD, Chief Operating Officer Andrea Va... |
| 15.09.2025 | uMotif Recognized as a Major Contender in Everest Group's Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix® Assessment 2025 | The modern, all-in-one uMotif platform integrates best-in-class eConsent and eCOA solutions.
Inaugural participation in market survey earns uMotif high rating in measurement of vision and capability to deliver eCOA products successfully; va... |
| 17.09.2024 | uMotif Showcases Modern eCOA/ePRO and eConsent to Ease Patient and Site Journey in Clinical Trials, Real-World Studies at Fall 2024 Life Sciences Conferences | Best-in-class eCOA/ePRO and site solutions including eConsent for faster, quality clinical trials and real-world studies
Executives including CEO Steve Rosenberg, Chief Patient Officer Bruce Hellman, Chief Scientific Officer Florence Mowlem... |
| 10.09.2024 | uMotif Names Florence Mowlem, PhD Chief Scientific Officer, Supporting Design and Delivery of Most Modern eCOA/ePRO, eConsent for Clinical Trials and Real-World Studies | Florence Mowlem, PhD, uMotif Chief Scientific Officer
Mowlem renowned as innovator in digitizing the capture of COAs including PROs and ClinROs to help sponsors meet the scientific and regulatory needs of clinical research and development
B... |
| 04.09.2024 | uMotif Buys ClinOne; Integrates Robust Platform of Site Applications Including eConsent into the Most Modern eCOA/ePRO Platform for Clinical Trials, Real-World Studies | uMotif CEO Steve Rosenberg
Brings best-in class enterprise consent management, clinical site productivity tools, innovative solutions for increasing trial awareness to HCPs, plus Uber Health patient transportation
BOSTON and LONDON, Sept. 4... |
| 09.11.2023 | uMotif and Cogstate Power CNS Research, Combining Patient-Centric eCOA/ePRO Data Capture Platform with Market-Leading Cognitive Solutions | uMotif
Companies building on existing studies in areas including psychedelics to better support CNS research with innovations to quantifiably increase data quality, improve study timelines, and enhance the clinical trial site and patient ex... |
| 20.09.2023 | uMotif CEO Steve Rosenberg, Visionary eClinical Technology Senior Executive and Innovator, Named to PharmaVoice 100 Most Influential, Inspiring People in Life Sciences | Steve Rosenberg, CEO of uMotif
Second PharmaVoice 100 honor for incisive leader; Rosenberg's vision and pragmatism help commercialize and advance the adoption of transformative technologies including eCOA/ePRO to accelerate clinical researc... |
| 31.05.2023 | University of Manchester Study Using uMotif Next-Generation eCOA/ePRO Data Capture App Reveals Significant Ethnic Disparities in Pain Recognition and Management | Our research underscores the necessity of putting patients first when designing self-reporting apps. Meeting patients where they are will enable vast improvements in healthcare, and open clinical research to a massive, diverse patient popul... |
| 08.05.2023 | Next-Generation eCOA/ePRO Provider uMotif Welcomes SAFIRA Clinical Research Co-founder and Clinical Trial Technology Innovator Willie Muehlhausen as Scientific Advisor | Wilhelm Muehlhausen, SAFIRA Clinical Research Co-founder 'We’re delighted to welcome Willie Muehllhausen as a Scientific Advisor. He has a remarkable track record of advancing technologies that make clinical trials run faster and smoother f... |
| 08.05.2023 | uMotif and Veramed Partner to Offer Advanced Biostatistical Data Analysis, Visualization Combined with Industry-Leading Patient eCOA/ePRO Data Capture and Analytics | "By working with Veramed, we can offer customers significant increases in the benefit they get from collecting and analyzing huge volumes of solid eCOA/ePRO data, for any therapeutic area, geography, or patient population." -uMoti... |
| 15.03.2023 | Life Science and Healthcare Industry Executive Adam Deutsch Joins uMotif Board as Company Brings the Next-Generation of eCOA/ePRO to Expanding Global Market | Adam Deutsch, uMotif Board Member “Adam Deutsch has an impeccable track record of guiding the growth of private and public companies in our industry...” – Steve Rosenberg, CEO of uMotif
BOSTON (PRWEB) March 15, 2023
uMotif – one of the clin... |
| 14.02.2023 | uMotif Wins SCOPE Summit Best of Show Award for First New Validated Data Capture Innovation Since Paper Instruments Deployed on Smartphones, for Next-Generation eCOA/ePRO | 'Our guiding principle is that clinical research patients are heroes. We give them technology to keep them motivated, active and compliant. When patients stay engaged, sponsors and CROs capture more and better-quality data, so they can spee... |
| 07.02.2023 | uMotif and ActiGraph Partner to Deliver Unmatched Patient Centric Solutions with Next Generation eCOA/ePRO, and Wearable Devices for Clinical Trials, Real-World Studies | PENSACOLA, Fla. and BOSTON (PRWEB) February 07, 2023
uMotif – one of the clinical trial technology market’s fastest growing companies – and ActiGraph, a pioneer and leading provider of wearable remote monitoring technology, announced a part... |
| 02.02.2023 | Newest uMotif Product Release Builds on Track Record of Delivering Patient-Centric, Next-Gen eCOA/ePRO for Faster, Higher Quality Clinical Trials, Real-World Studies | BOSTON (PRWEB) February 02, 2023
uMotif – one of the clinical trial technology market’s fastest growing companies – continues to accelerate the pace and quality of clinical, real-world and post-marketing research with new enhancements to it... |
| 18.11.2022 | uMotif Announces First New Validated Innovation in eCOA/ePRO Since Paper Instruments Were Deployed on Smartphones | "uMotif is the only eCOA/ePRO company that started by working with patients to capture their health and well-being to share with their physicians. Today’s announcement underscores our unique ability to make it easier and more convenien... |
| 11.10.2022 | uMotif to Showcase How Transformative eCOA/ePRO Technology Enables Faster, More Engaging Trials and Real-World Studies at Premier Pharma and Biotech Industry Events | Executives including CEO Steve Rosenberg, Co-Founder & Chief Patient Officer Bruce Hellman to discuss the eCOA/ePRO market – what's working, what's wrong, and what patients need now
BOSTON, Oct. 10, 2022 /PRNewswire-PRWeb/ -- uMotif, on... |
| 10.10.2022 | uMotif to Showcase How Transformative eCOA/ePRO Technology Enables Faster, More Engaging Trials and Real-World Studies at Premier Pharma and Biotech Industry Events | uMotif will share its unique perspective on how pharma and biotech can and must adopt market-tested eCOA/ePRO solutions that engage patients to run better trials and real-world studies at top industry events during Q4.
BOSTON (PRWEB) Octobe... |
| 21.06.2022 | uMotif and ClinOne Unify eCOA/ePRO and eConsent to Improve the Participant Experience and Endpoint Data Quality in Global Clinical Trials | ClinOne is proud to provide our eConsent customers direct access to uMotif’s intuitive, trusted eCOA/ePRO. Our expanded platform provides essential solutions that blend clinical trial activities into the flow of everyday life, making it eas... |
| 27.05.2022 | London-based uMotif raises €23.8M for its scalable patient-centred data capture platform | London-based uMotif, a company that provides a scalable patient-centred data capture platform for modern research, announced that it has raised $25.5M (approximately €23.80M) in a fresh round of funding. The investment came from a fund mana... |
| 26.05.2022 | Clinical trial tech company uMotif scores $25.5M to continue international expansion | Photo: uMotif |
| 04.09.2020 | Healthtech startup uMotif lands £5M | AlbionVC has led a £5 million Series A for uMotif, the London-based developer of an app that records and measures patients' health during clinical trials. The capital will go toward its international expansion and the development of new stu... |
| 03.09.2020 | Medtech startup uMotif raises £5M from AlbionVC, as COVID-19 accelerates remote clinical studies | Medtech startup uMotif has an app that allows patients to monitor themselves for treatments or drug trials, which then feeds into a platform, allowing a much faster approach to clinical studies. It has now raised £5 million in a Series A in... |
| 03.09.2020 | Daily funding roundup - Sept 3rd, 2020 | Anima has raised $2.5M; Avo landed a $3M; Reserved.AI secured $3.3M; Aspinity picks up $5.3
Anima: Anima is a New York-based no-code design startup. Anima has raised $2.5 million in seed funding from Hetz Ventures and Israeli angel investor... |
| 03.09.2020 | London-based uMotif raises £5m Series A | London-based uMotif – the patient-centric data capture software company has raised £5 million in a Series A investment round led by existing investor AlbionVC.
The funding, which also saw participation from Oslo-based DNV-GL and existing an... |
| 03.09.2020 | London-based uMotif scoops €5.6M for patient-centric and decentralised approach to clinical studies | Life sciences companies are increasingly embracing decentralised and virtual study designs – where patient consent and data are captured using their own devices from wherever they are located.
Back in 2012, London-based uMotif started as a ... |
| 03.09.2020 | London’s uMotif secures £5 million to decentralise clinical trials and get therapies to patients faster | London-based uMotif, a software that captures patient data for clinical studies, has raised £5 million in a Series A round led by existing investor AlbionVC, with participation from Norwegian firm DNV GL and angel investors.
By creating a m... |
| 28.06.2018 | Healthcare Data Capture Company uMotif Secures £2.4M | uMotif, a London, UK-based data capture company putting patients at the centre of clinical research, raised £2.4m in funding.
The round was led by Albion Capital, with participation from several angel investors.
The company intends to use t... |
| 26.06.2018 | uMotif gets $3.2M for patient-first approach to clinical trial innovation | |
| 23.03.2017 | Establishing the North as a digital health powerhouse | This article was originally posted on the Tech North website.
Dr Hakim Yadi OBE is Chief Executive of the Northern Health Science Alliance.
The North of England led the world during the industrial revolution. It is now at the forefront of... |
| 21.02.2015 | Guest Post: Lloyd Price of Zesty Discusses the UK’s Healthtech Revolution | This article was originally posted on the Tech City UK website.
Is Healthtech poised to break through in London in 2015 like Fintech in 2013? We hear the opinion of Lloyd Price, Co-founder of Zesty
Yes, 2015 is set to be the most exciting... |
| 23.01.2013 | Innovative UK Technology SMEs Chosen for Web Mission to India 2013 | LONDON, UK, 23rd January 2013 – Today, the UK’s best digital, wireless and mobile software technology companies have been awarded their place on Web Mission 2013, an entrepreneur-led mission to India, to accelerate their business in the gro... |
